WO2014170493A3 - Vecteur d'alphavirus - Google Patents

Vecteur d'alphavirus Download PDF

Info

Publication number
WO2014170493A3
WO2014170493A3 PCT/EP2014/058028 EP2014058028W WO2014170493A3 WO 2014170493 A3 WO2014170493 A3 WO 2014170493A3 EP 2014058028 W EP2014058028 W EP 2014058028W WO 2014170493 A3 WO2014170493 A3 WO 2014170493A3
Authority
WO
WIPO (PCT)
Prior art keywords
heterologous protein
alphavirus vector
sequence
nsp3
nsp1
Prior art date
Application number
PCT/EP2014/058028
Other languages
English (en)
Other versions
WO2014170493A2 (fr
Inventor
Clayton BEARD
Giulietta MARUGGI
Peter W. Mason
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of WO2014170493A2 publication Critical patent/WO2014170493A2/fr
Publication of WO2014170493A3 publication Critical patent/WO2014170493A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18534—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/36011—Togaviridae
    • C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
    • C12N2770/36121—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/36011—Togaviridae
    • C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
    • C12N2770/36141—Use of virus, viral particle or viral elements as a vector

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

L'invention concerne d'une manière générale des vecteurs d'alphavirus recombinants comprenant un 5'-UTR, des séquences codant des gènes non de structure nsP1, nsP2, nsP3 et nsP4, et une séquence qui est reliée de manière fonctionnelle à une séquence de contrôle d'expression et codant pour une protéine hétérologue; mis au point pour produire des niveaux souhaités d'expression de protéine hétérologue et/ou d'induction d'interféron.
PCT/EP2014/058028 2013-04-19 2014-04-19 Vecteur d'alphavirus WO2014170493A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP13164381.9 2013-04-19
EP13164381 2013-04-19

Publications (2)

Publication Number Publication Date
WO2014170493A2 WO2014170493A2 (fr) 2014-10-23
WO2014170493A3 true WO2014170493A3 (fr) 2014-12-11

Family

ID=48141801

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2014/058028 WO2014170493A2 (fr) 2013-04-19 2014-04-19 Vecteur d'alphavirus

Country Status (1)

Country Link
WO (1) WO2014170493A2 (fr)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017162265A1 (fr) * 2016-03-21 2017-09-28 Biontech Rna Pharmaceuticals Gmbh Arn à réplication trans
JP7250520B2 (ja) 2016-04-13 2023-04-03 ヤンセン ファーマシューティカルズ，インコーポレーテッド 組換えアルテリウイルスレプリコン系およびその使用
WO2018075235A1 (fr) * 2016-10-17 2018-04-26 Synthetic Genomics, Inc. Systèmes réplicons de virus recombinants et leurs utilisations
US11845939B2 (en) 2016-12-05 2023-12-19 Janssen Pharmaceuticals, Inc. Compositions and methods for enhancing gene expression
EA202091513A1 (ru) 2017-12-19 2020-09-09 Янссен Сайенсиз Айрлэнд Анлимитед Компани Вакцины против вируса гепатита b (hbv) и их применение
EA202091516A1 (ru) 2017-12-19 2020-11-03 Янссен Сайенсиз Айрлэнд Анлимитед Компани Способы и композиции для индукции иммунного ответа против вируса гепатита b (hbv)
EA202091517A1 (ru) 2017-12-19 2020-11-03 Янссен Сайенсиз Айрлэнд Анлимитед Компани Способы и устройство для доставки вакцин против вируса гепатита b (hbv)
US11083786B2 (en) 2018-01-19 2021-08-10 Janssen Pharmaceuticals, Inc. Induce and enhance immune responses using recombinant replicon systems
JP2022538847A (ja) * 2019-06-27 2022-09-06 イーエムディ・ミリポア・コーポレイション 不死化タンパク質を発現する自己複製性ｒｎａベクターによる細胞増殖
AU2021233816A1 (en) 2020-03-09 2022-10-06 Arcturus Therapeutics, Inc. Coronavirus vaccine compositions and methods
BR112022021828A2 (pt) * 2020-04-30 2023-01-17 Vlp Therapeutics Inc Imunoterapia de citocina
US11613561B2 (en) 2021-03-19 2023-03-28 Tiba Biotech, Llc Artificial alphavirus-derived RNA replicon expression systems

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005113782A1 (fr) * 2004-05-18 2005-12-01 Alphavax, Inc. Vecteurs alpha viraux dérivés du tc-83, particules et méthodes
US20060198854A1 (en) * 2004-12-28 2006-09-07 Peter Pushko Vector platforms derived from the alphavirus vaccines
WO2011139717A1 (fr) * 2010-04-26 2011-11-10 Novartis Ag Production améliorée de particules de réplicon de virus dans des cellules d'encapsidation

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005113782A1 (fr) * 2004-05-18 2005-12-01 Alphavax, Inc. Vecteurs alpha viraux dérivés du tc-83, particules et méthodes
US20060198854A1 (en) * 2004-12-28 2006-09-07 Peter Pushko Vector platforms derived from the alphavirus vaccines
WO2011139717A1 (fr) * 2010-04-26 2011-11-10 Novartis Ag Production améliorée de particules de réplicon de virus dans des cellules d'encapsidation

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
SEREGIN A V ET AL: "TC83 replicon vectored vaccine provides protection against Junin virus in guinea pigs", VACCINE, ELSEVIER LTD, GB, vol. 28, no. 30, 5 July 2010 (2010-07-05), pages 4713 - 4718, XP027118985, ISSN: 0264-410X, [retrieved on 20100702] *

Also Published As

Publication number Publication date
WO2014170493A2 (fr) 2014-10-23

Similar Documents

Publication Publication Date Title
WO2014170493A3 (fr) Vecteur d'alphavirus
MX2021004032A (es) Replicones basados en alfavirus para la administracion de bioterapeuticos.
ZA201803443B (en) Viral vectors encoding recombinant fviii variants with increased expression for gene therapy of hemophilia a
WO2013063383A3 (fr) Vecteurs codant pour un facteur de viabilité des cônes dérivé des bâtonnets
SG10201901735XA (en) Recombinant modified vaccinia virus ankara (mva) filovirus vaccine
EP2550359A4 (fr) Vecteurs exprimant des protéines thérapeutiques de manière conditionnelle, cellules hôtes comprenant les vecteurs, et utilisations associées
MX363427B (es) Mutante de epimerasa psicosa y metodo para preparar psicosa mediante el uso del mismo.
EP4223772A3 (fr) Gene optimise du facteur viii
WO2016075473A3 (fr) Thérapie génique par le facteur ix
EP3505629A4 (fr) Arnsi d'interleukine humaine 6, vecteur car-t d'expression recombinante, et leur procédé de construction et utilisation
MX2016014635A (es) Reduccion de la conversion de nicotina a nornicotina en plantas.
IL280637A (en) Viral vectors encoding recombinant FIX with increased expression for gene therapy of hemophilia B
MX2018010850A (es) Métodos para producir proteínas de fusión de toxina diftérica monoméricas y libres de agregados y usos terapéuticos.
MX2020006567A (es) Particula de replicon de alfavirus.
WO2014150449A3 (fr) Promoteurs de soja constitutifs
IL259295B1 (en) Viral vectors encoding recombinant FVIII variants with increased expression for gene therapy in hemophilia A
GB2547115A (en) Craft for use on a body of water and transport and control system therefore
MX2016011300A (es) Vectores recombinantes del virus isfahan.
HRP20210265T1 (hr) Terapije na temelju reverzne transkriptaze telomeraze
PH12019500578A1 (en) New promoters
MX2014011890A (es) Secuencias de acidos nucleicos y peptidos/proteinas de la familia de ft que proporcionan propiedades represoras de la floracion en plantas de tabaco y en plantas transgenicas transformadas con las mismas.
MX367093B (es) Vacuna semi-viva del virus sincitial respiratorio.
NZ743236A (en) Fmdv and e2 fusion proteins and uses thereof
MX2020001655A (es) Vacuna vph.
PH12020500526A1 (en) Paramyxoviridae expression system

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 14718594

Country of ref document: EP

Kind code of ref document: A2

122 Ep: pct application non-entry in european phase

Ref document number: 14718594

Country of ref document: EP

Kind code of ref document: A2